Efficacy News and Research

RSS
Nuon Therapeutics NU1618 phase 2a study in hyperuricemia meets primary endpoint

Nuon Therapeutics NU1618 phase 2a study in hyperuricemia meets primary endpoint

NexMed's NexACT-based topical psoriasis treatment bioequivalent to Talconex

NexMed's NexACT-based topical psoriasis treatment bioequivalent to Talconex

Nymox near completion of new NX-1207 follow-up study for BPH

Nymox near completion of new NX-1207 follow-up study for BPH

New data from Phase 2a trial support further development of BMS-945429/ALD518 monoclonal antibody for RA

New data from Phase 2a trial support further development of BMS-945429/ALD518 monoclonal antibody for RA

Results from ICH compliant Phase II study of MRX-4 presented at EAACI Congress

Results from ICH compliant Phase II study of MRX-4 presented at EAACI Congress

Global drug distribution programs one factor in hastening drug resistance, report says

Global drug distribution programs one factor in hastening drug resistance, report says

Study aims at determining optimal dose of nab-paclitaxel with carboplatin as first-line therapy for NSCLC

Study aims at determining optimal dose of nab-paclitaxel with carboplatin as first-line therapy for NSCLC

Vitamin D may help reduce incidence, severity of viral respiratory tract infections: Study

Vitamin D may help reduce incidence, severity of viral respiratory tract infections: Study

Immunomedics initiates dosing in milatuzumab-doxorubicin conjugate Phase I/II trial for relapsed multiple myeloma

Immunomedics initiates dosing in milatuzumab-doxorubicin conjugate Phase I/II trial for relapsed multiple myeloma

Galera Therapeutics completes Series 1 financing

Galera Therapeutics completes Series 1 financing

Cytokine PharmaSciences completes misoprostol vaginal insert Phase II study

Cytokine PharmaSciences completes misoprostol vaginal insert Phase II study

Biogen Idec initiates enrollment in Phase II BG-12 combination trial for relapsing-remitting multiple sclerosis

Biogen Idec initiates enrollment in Phase II BG-12 combination trial for relapsing-remitting multiple sclerosis

Positive clinical trial results for Anacor Pharmaceuticals' AN2728 announced

Positive clinical trial results for Anacor Pharmaceuticals' AN2728 announced

Endosense launches ProForce Registry Study of TactiCath force-sensing ablation catheter

Endosense launches ProForce Registry Study of TactiCath force-sensing ablation catheter

Alexion's Soliris may benefit patients with thrombotic microangiopathy from uncontrolled complement activation

Alexion's Soliris may benefit patients with thrombotic microangiopathy from uncontrolled complement activation

Inovio commences immunization in U.S. Phase I clinical trial of SynCon H5N1 influenza DNA vaccine

Inovio commences immunization in U.S. Phase I clinical trial of SynCon H5N1 influenza DNA vaccine

Pieris commences PRS-050 anti-VEGF Anticalin Phase I clinical trial for cancer

Pieris commences PRS-050 anti-VEGF Anticalin Phase I clinical trial for cancer

Project ideas needed from worldwide Alzheimer Disease research community

Project ideas needed from worldwide Alzheimer Disease research community

Trubion announces Pfizer's decision to discontinue development of TRU-015 for RA

Trubion announces Pfizer's decision to discontinue development of TRU-015 for RA

Entomologists to develop genetically engineered bacteria for killing mosquito larvae

Entomologists to develop genetically engineered bacteria for killing mosquito larvae

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.